What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
Regular touch-up sessions every three to six months can also extend the effects, with the possibility of requiring fewer units of Botox over time due to the potential cumulative effect of the treatments
As a reminder, SELECT enrolled 17,604 adults who were 45 years or older, overweight or obese, without diabetes and had a diagnosis of cardiovascular disease, including prior myocardial infarction, stroke, and/or peripheral artery disease
Typical TB 500 Dosing Strategy Loading phase: 4-6 mg per week Maintenance phase: 2-4 mg weekly Administered via injection The initial phase usually lasts four to six weeks, with adjustments based on the individual response
Sci Rep (2021) 11(1):21350
Shop Now, Pay Later with Klarna Available online and in-store, you can now split your purchase into four interest-free payments with Klarna*
